Speech treatment improves dysarthria in multisystemic ataxia: a rater-blinded, controlled pilot-study in ARSACS

Redenlab partnered with investigators in Australia and Germany to conduct dysarthria treatment trial in ataxia published in Journal of Neurology

Abstract: We aimed to provide proof-of-principle evidence that intensive home-based speech treatment can improve dysarthria in complex multisystemic degenerative ataxias, exemplified by autosomal recessive spastic ataxia Charlevoix-Saguenay (ARSACS). Feasibility and piloting efficacy of speech training specifically tailored to cerebellar dysarthria was examined through a 4-week program in seven patients with rater-blinded assessment of intelligibility (primary outcome) and naturalness and acoustic measures of speech (secondary outcomes) performed 4 weeks before, immediately prior to, and directly after training (intraindividual control design). Speech intelligibility and naturalness improved post treatment. This provides piloting evidence that ataxia-tailored speech treatment might be effective in degenerative cerebellar disease.

See here for study details

Related Post

  • Posted on 17 November, 2022
    The 4th Annual Kabuki Syndrome Foundation Research Conference to be held virtually on Friday, November 4, 2022. The Annual Conference...
    • Posted on 21 October, 2022
      Join World BI and Redenlab for the 20th Clinical Trials Innovation Programme, to learn from experts in the drug development...
      • Posted on 15 July, 2022
        MEDIA RELEASEFRIDAY 15 JULY 2022 As many as 70% of people who experience stuttering have a family member who also...